Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

The Biomedical Advanced Research and Development Authority (BARDA) is issuing BAA‑23‑100‑SOL‑00004 to acquire flexible vaccine manufacturing technologies and related development services for SARS‑CoV‑2 and other high‑priority viral threats, including respiratory viruses and hemorrhagic‑fever agents. Offerors must independently furnish all professional, technical, and administrative personnel, equipment, and facilities needed to execute a detailed Statement of Work (SOW) that addresses project management, pre‑clinical/clinical studies, manufacturing, and regulatory strategy. Proposals must include a Market Research Abstract (submitted before the full proposal) and are strongly encouraged to coordinate with the Technical POC (FASTxBAA@hhs.gov) to obtain feedback. All efficacy data against the latest viral variants must be provided, and the SOW must be segmented into non‑severable work periods with clear go/no‑go milestones. Key technical requirements include a manufacturing platform capable of advancing a vaccine candidate from gene sequence to an IND submission within six months, demonstrating applicability to multiple infectious‑disease targets, and scaling to at least one million doses. The technology should improve regulatory and safety aspects, reduce cost of goods, and shorten development timelines. Offerors must follow the specified cover‑page format, attach the Government Notice for Handling and Submitting Proposals behind the title page, and may propose option periods to advance candidates on secondary targets agreed with the Government.

Notice ID

d832248e72e14c3c8cee96ee3c8b2170

Solicitation Number

BAA-23-100-SOL-00004

NAICS Code

541714

Classification Code

AN13